AVAC

Global Advocacy for HIV Prevention

The Years Ahead in Biomedical HIV Prevention Research

Status of select biomedical HIV prevention clinical trials

Efficacy Trial 2017 2018 2019 2020 **HOPE (MTN 025)** Open-label trial of the once-monthly slow-release dapivirine vaginal ring; ongoing in 2,500 women in Malawi, South Africa, Uganda, Zimbabwe **Vaginal Ring Dapivirine Ring DREAM (IPM 032)** Open-label trial of the once-monthly slow-release dapivirine vaginal ring; ongoing in 1,400 women in South Africa and Uganda **AMP (HVTN 704/** Randomized controlled trial of the VRC01 antibody infused every two months; ongoing in 2,700 MSM and transgender persons in Brazil, Peru, Switzerland and US **HPTN 085)** Antibodv **AMP (HVTN 703/ HPTN 081)** Randomized controlled trial of the VRCO1 antibody infused every two months; ongoing in 1,500 women in Botswana, Kenya, Malawi, Mozambique, Tanzania, South Africa, Zimbabwe **Oral PrEP DISCOVER** Randomized controlled trial of once-daily F/TAF as PrEP; ongoing in 5,000 MSM and transgender women at approximately 90 sites in Europe and the Americas (Descovy) **HPTN 083 Long-acting** Randomized controlled trial of injectable cabotegravir every two months; ongoing in 4500 MSM and transgender persons in Argentina, Brazil, India, Peru, South Africa, Thailand, US, Vietnam Injectable Cabotegravir **HPTN 084** Randomized unblinded trial of injectable cabotegravir every two months; planned for women in Southern and East African countries **Preventive HIV Vaccine** ALVAC/gp120 **HVTN 702** Randomized controlled trial of ALVAC/gp120 prime-boost with MF59 adjuvant, five doses over 12 months, ongoing in 5,400 men and women in South Africa w/MF59 Ad26/MVA **HVTN 705/HPX2008** boost Randomized controlled trial of Ad26 prime and MVA boost; planned for men and women in the Americas and Southern and East Africa



Open-label Randomized Controlled Randomized Unblinded